LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ:CYTR), today announced that RXi Pharmaceuticals Corporation, its majority-owned subsidiary, has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC) to register the shares of RXi common stock that will be distributed to CytRx stockholders. The plan to distribute the RXi shares was previously announced by CytRx. The registration statement filed by RXi also covers shares of RXi common stock that will be awarded to certain directors, officers and other employees of CytRx. The RXi shares to be held by CytRx after the distribution and award transactions have been registered for resale by CytRx pursuant to the registration statement.
